RenovoDerm, a wound care device company, announced today that Michael Morello has joined the company’s senior leadership team as Vice President of Sales & Marketing.
A new position for the company, Morello will be responsible for developing and implementing strategies to take RenovoDerm products, including the recently FDA cleared Phoenix Wound MatrixTM, to federal and commercial markets. In addition to delivering on the overall marketing and sales strategy, he will also be responsible for day-to-day marketing activities, such as messaging, customer pricing, reimbursement strategy, contracting third-party vendors, and expense management.
Jed Johnson will be representing RenovoDerm at the 2017 Heal Ohio Wound Care Conference on Thursday, November 2nd. Heal Ohio is a statewide collaborative that aims to unite scientists, healthcare professionals, and commercial partners who share a common vision and mission to solve problems associated with wound care. In doing this, it will serve to bridge the gaps that exist between clinics, research, business, and patients.
The 2017 Heal Ohio Conference will be devoted to health professional presentations and feature informative learning sessions and keynote addresses. Activities are expected to provide an atmosphere rich in collaboration and networking for both career and research advancement.
On July 25, RenovoDerm held an all-day executive reimbursement workshop led by Kathleen Schaum, President of Kathleen D. Schaum & Assoc., Inc. Ms. Schaum is a nationally recognized wound care reimbursement strategy consultant and educator with nearly 50 years of industry experience. Ms. Schaum led the RenovoDerm team in crafting its reimbursement strategy for the Phoenix Wound Care Matrix, which included coding, coverage, and payment. The seminar also focused on identifying and targeting the most applicable markets for the Phoenix and creating a detailed timeline to achieve a product launch.
The workshop was very successful. After significant dialogue with Ms. Schaum, the RenovoDerm team is now better equipped to effectively earn a strategic reimbursement code, implement a detailed sales and marketing strategy, and utilize valuable resources to maximize the company’s value.
Today, RenovoDerm announced that the U.S. Food and Drug Administration (FDA) has cleared its proprietary product, the Phoenix Wound Matrix.
The Phoenix Wound Matrix is a fully resorbable electrospun device designed to mimic the extracellular matrix (ECM) found naturally in the body. This product will be used for the treatment of acute, chronic, and burn wounds, which continues to be a concern for both doctors and patients.